Tissue factor mediates inflammation

被引:124
作者
Chu, AJ [1 ]
机构
[1] Shantou Univ, MRC, Shantou 515063, Guangdong, Peoples R China
关键词
tissue factor; inflammation; blood coagulation; thrombosis; protease-activated receptor; sepsis;
D O I
10.1016/j.abb.2005.06.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The role of tissue factor (TF) in inflammation is mediated by blood coagulation. TF initiates the extrinsic blood coagulation that proceeds as an extracellular signaling cascade by a series of active serine proteases: FVIIa, FXa, and thrombin (FIIa) for fibrin clot production in the presence of phospholipids and Ca2+. TF upregulation resulting from its enhanced exposure to clotting factor FVII/ FVIIa often manifests not only hypercoagulable but also inflammatory state. Coagulant mediators (FVIIa, FXa, and FIIa) are pro-inflammatory, which are largely transmitted by protease-activated receptors (PAR) to elicit inflammation including the expression of tissue necrosis factor, interleukins, adhesion molecules (MCP-1, ICAM-1, VCAM-1, selectins, etc.), and growth factors (VEGF, PDGF, bFGF, etc.). In addition, fibrin, and its fragments are also able to promote inflammation. In the event of TF hypercoagulability accompanied by the elevations in clotting signals including fibrin overproduction, the inflammatory consequence could be enormous. Antagonism to coagulation-dependent inflammation includes (1) TF downregulation, (2) anti-coagulation, and (3) PAR blockade. TF downregulation and anti-coagulation prevent and limit the proceeding of coagulation cascade in the generation of proinflarnmatory coagulant signals, while PAR antagonists block the transmission of such signals. These approaches are of significance in interrupting the coagulation-inflammation cycle in contribution to not only anti-inflammation but also anti-thrombosis for cardioprotection. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:123 / 132
页数:10
相关论文
共 189 条
  • [1] Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages
    Abe, Y
    Hashimoto, S
    Horie, T
    [J]. PHARMACOLOGICAL RESEARCH, 1999, 39 (01) : 41 - 47
  • [2] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
    Abraham, E
    Reinhart, K
    Opal, S
    Demeyer, I
    Doig, C
    Rodriguez, AL
    Beale, R
    Svoboda, P
    Laterre, PF
    Simon, S
    Light, B
    Spapen, H
    Stone, J
    Seibert, A
    Peckelsen, C
    De Deyne, C
    Postier, R
    Pettilä, V
    Sprung, CL
    Artigas, A
    Percell, SR
    Shu, V
    Zwingelstein, C
    Tobias, J
    Poole, L
    Stolzenbach, JC
    Creasey, AA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02): : 238 - 247
  • [3] Inhibition of cellular action of thrombin by N3-cyclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist
    Ahn, HS
    Foster, C
    Boykow, G
    Stamford, A
    Manna, M
    Graziano, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 60 (10) : 1425 - 1434
  • [4] Inhibition of factor Xa suppresses the expression of tissue factor in human monocytes and lipopolysaccharide-induced endotoxemia in rats
    Akahane, K
    Okamoto, K
    Kikuchi, M
    Todoroki, F
    Higure, A
    Ohuchida, T
    Kitahara, K
    Takeda, S
    Itoh, H
    Ohsato, K
    [J]. SURGERY, 2001, 130 (05) : 809 - 818
  • [5] Modified proteinase-activated receptor-1 and-2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin
    Al-Ani, B
    Saifeddine, M
    Wijesuriya, SJ
    Hollenberg, MD
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (02) : 702 - 708
  • [6] Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits
    Aldea, GS
    Soltow, LO
    Chandler, WL
    Triggs, CM
    Vocelka, CR
    Crockett, GI
    Shin, YT
    Curtis, WE
    Verrier, ED
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (04) : 742 - 755
  • [7] Suppressive effects of anti-inflammatory agents on human endothelial cell activation and induction of heat shock proteins
    Amberger, A
    Hala, M
    Saurwein-Teissl, M
    Metzler, B
    Grubeck-Loebenstein, B
    Xu, QB
    Wick, G
    [J]. MOLECULAR MEDICINE, 1999, 5 (02) : 117 - 128
  • [8] Local delivery of a tissue factor antibody reduces early leukocyte infiltration but fails to limit intimal hyperplasia in experimental vein grafts
    Annex, BH
    Davies, MG
    Fulton, GJ
    Huynh, TTT
    Channon, KM
    Ezekowitz, MD
    Hagen, PO
    [J]. JOURNAL OF SURGICAL RESEARCH, 1998, 80 (02) : 164 - 170
  • [9] The agonist of the protease-activated receptor-1 (PAR1) but not PAR3 mimics thrombin-induced vascular endothelial growth factor release in human vascular smooth muscle cells
    Arisato, T
    Sarker, KP
    Kawahara, K
    Nakata, M
    Hashiguchi, T
    Osame, M
    Kitajima, I
    Maruyama, I
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2003, 60 (08) : 1716 - 1724
  • [10] Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells
    Asokananthan, N
    Graham, PT
    Fink, J
    Knight, DA
    Bakker, AJ
    McWilliam, AS
    Thompson, PJ
    Stewart, GA
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (07) : 3577 - 3585